Article
Hematology
Freda K. Stevenson, Francesco Forconi, Thomas J. Kipps
Summary: Research into chronic lymphocytic leukemia has led to significant improvements in the assessment and treatment of patients, with designer drugs now successfully targeting tumor cells based on their biology. Classifying CLL into unmutated (U) and mutated (M) diseases based on the mutational status of IGHV sequences reveals distinct origins, biology, and clinical behaviors for each. Despite advances, challenges such as cell-escape strategies and immunosuppression remain, necessitating continued research into CLL biology.
Article
Biochemistry & Molecular Biology
Kristan V. Piroeva, Charlotte Mcdonald, Charalampos Xanthopoulos, Chelsea Fox, Christopher T. Clarkson, Jan-Philipp Mallm, Yevhen Vainshtein, Luminita Ruje, Lara C. Klett, Stephan Stilgenbauer, Daniel Mertens, Efterpi Kostareli, Karsten Rippe, Vladimir B. Teif
Summary: This study compared the nucleosome positions in chronic lymphocytic leukemia (CLL) patients and healthy individuals, and found significant changes in nucleosome positioning in CLL. The spacing between nucleosomes was shortened, and changes in nucleosome occupancy were linked to chromatin remodeling and reduced DNA methylation. Nucleosome positioning can be used to classify CLL subtypes and monitor disease progression.
Article
Hematology
Fabienne Meier-Abt, Junyan Lu, Ester Cannizzaro, Marcel F. Pohly, Sandra Kummer, Sibylle Pfammatter, Laura Kunz, Ben C. Collins, Ferran Nadeu, Kwang Seok Lee, Peng Xue, Myriam Gwerder, Michael Roiss, Jennifer Huellein, Sebastian Scheinost, Sascha Dietrich, Elias Campo, Wolfgang Huber, Ruedi Aebersold, Thorsten Zenz
Summary: This study uncovered mutations affecting protein expression in CLL and identified signaling pathways associated with trisomy 12. STAT2 protein expression was linked to specific drug responses, providing a protein expression reference map for CLL.
Article
Multidisciplinary Sciences
Johannes Bloehdorn, Andrejs Braun, Amaro Taylor-Weiner, Billy Michael Chelliah Jebaraj, Sandra Robrecht, Julia Krzykalla, Heng Pan, Adam Giza, Gulnara Akylzhanova, Karlheinz Holzmann, Annika Scheffold, Harvey E. Johnston, Ru-Fang Yeh, Tetyana Klymenko, Eugen Tausch, Barbara Eichhorst, Lars Bullinger, Kirsten Fischer, Martin Weisser, Tadeusz Robak, Christof Schneider, John Gribben, Lekh N. Dahal, Mathew J. Carter, Olivier Elemento, Dan A. Landau, Donna S. Neuberg, Mark S. Cragg, Axel Benner, Michael Hallek, Catherine J. Wu, Hartmut Doehner, Stephan Stilgenbauer, Daniel Mertens
Summary: Understanding the complex genomics of chronic lymphocytic leukemia (CLL) has revealed distinct molecular subtypes with different prognostic implications, involving activation of epithelial-mesenchymal-transition (EMT) programs and genomic instability. Targeting these molecular subclasses may lead to new treatment strategies for CLL.
NATURE COMMUNICATIONS
(2021)
Article
Medicine, Research & Experimental
Chao Guo, Ya-yue Gao, Qian-qian Ju, Chun-xia Zhang, Ming Gong, Zhen-ling Li
Summary: The study identified co-expression modules and hub genes correlating with IGHV mutation status in CLL patients. These genes are associated with important signaling pathways and have prognostic value for CLL patients.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Hematology
Stavroula Ntoufa, Marina Gerousi, Stamatia Laidou, Fotis Psomopoulos, Georgios Tsiolas, Theodoros Moysiadis, Nikos Papakonstantinou, Larry Mansouri, Achilles Anagnostopoulos, Niki Stavrogianni, Sarka Pospisilova, Karla Plevova, Antonios M. Makris, Richard Rosenquist, Kostas Stamatopoulos
Summary: Recurrent mutations in the RPS15 gene have been found to rewire the translation program of primary CLL cells, reducing their translational efficiency, with effects not observed in cell lines. Specifically, RPS15 mutations alter the translation efficiency of other ribosomal proteins and regulatory elements, impacting key cellular processes and immune signaling.
Article
Genetics & Heredity
Pauline Robbe, Kate E. Ridout, Dimitrios V. Vavoulis, Helene Dreau, Ben Kinnersley, Nicholas Denny, Daniel Chubb, Niamh Appleby, Anthony Cutts, Alex J. Cornish, Laura Lopez-Pascua, Ruth Clifford, Adam Burns, Basile Stamatopoulos, Maite Cabes, Reem Alsolami, Pavlos Antoniou, Melanie Oates, Doriane Cavalieri, Genomics England Research Consortium, Cll Pilot Consortium, Jane Gibson, Anika Prabhu, Ron Schwessinger, Daisy Jennings, Terena James, Uma Maheswari, Marti Duran-Ferrer, Piero Carninci, Samantha J. L. Knight, Robert Mansson, Jim Hughes, James Davies, Mark Ross, David Bentley, Jonathan C. Strefford, Stephen Devereux, Andrew R. Pettitt, Peter Hillmen, Mark J. Caulfield, Richard S. Houlston, Jose Martin-Subero, Anna Schuh
Summary: This study reports the whole-genome sequencing of 485 chronic lymphocytic leukemia patients and identifies a range of recurrent coding and noncoding genetic mutations. The study also provides a high-resolution map of structural variants, copy number changes, and global genome features, and demonstrates the relationship of these features with clinical outcomes.
Article
Medicine, General & Internal
Han-ying Huang, Yun Wang, Tobias Herold, Robert Peter Gale, Jing-zi Wang, Liang Li, Huan-xin Lin, Yang Liang
Summary: The study found that the expression of immune-related genes in patients with chronic lymphoblastic leukemia can serve as an independent predictor of survival, and the immune risk score (IRS) can predict the survival risk of patients.
FRONTIERS IN MEDICINE
(2022)
Article
Medicine, Research & Experimental
Andrea N. Mazzarello, Eva Gentner-Goebel, Marcus Duehren-von Minden, Tatyana N. Tarasenko, Antonella Nicolo, Gerardo Ferrer, Stefano Vergani, Yun Liu, Davide Bagnara, Kanti R. Rai, Jan A. Burger, Peter J. McGuire, Palash C. Maity, Hassan Jumaa, Nicholas Chiorazzi
Summary: This study found that IgM plays a critical and selective role in BCR signaling and B cell fate decisions in chronic lymphocytic leukemia (CLL), which may open up new avenues for CLL therapy.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Hematology
Serena Matis, Anna Grazia Recchia, Monica Colombo, Martina Cardillo, Marina Fabbi, Katia Todoerti, Sabrina Bossio, Sonia Fabris, Valeria Cancila, Rosanna Massara, Daniele Reverberi, Laura Emionite, Michele Cilli, Giannamaria Cerruti, Sandra Salvi, Paola Bet, Simona Pigozzi, Roberto Fiocca, Adalberto Ibatici, Emanuele Angelucci, Massimo Gentile, Paola Monti, Paola Menichini, Gilberto Fronza, Federica Torricelli, Alessia Ciarrocchi, Antonino Neri, Franco Fais, Claudio Tripodo, Fortunato Morabito, Manlio Ferrarini, Giovanna Cutrona
Summary: A specific miRNA (miR-146b-5p) in chronic lymphocytic leukemia (CLL) regulates the expression of IL-12R(31 and the expansion of leukemic cells, thus playing a role in the pathogenesis and treatment of CLL.
Article
Medicine, General & Internal
Barbara Eichhorst, Carsten U. Niemann, Arnon P. Kater, Moritz Fuerstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindstrom, Caspar da Cunha-Bang, Christof Schneider, Christian B. Poulsen, Thomas Illmer, Bjoern Schoettker, Thomas Noesslinger, Ann Janssens, Ilse Christiansen, Michael Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jaeger, Maria B. L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna-Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens-Martin Wendtner, Karl A. Kreuzer, Matthias Ritgen, Monika Brueggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek
Summary: In fit patients with CLL, venetoclax-obinutuzumab, with or without ibrutinib, showed superior results compared to chemoimmunotherapy as a first-line treatment, with higher rates of undetectable minimal residual disease and progression-free survival.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Vi Lam, Carly Roleder, Tingting Liu, Nur Bruss, Scott Best, Xiaoguang Wang, Tycel Phillips, Geoffrey Shouse, Allison J. Berger, Lapo Alinari, Lili Wang, Tanya Siddiqi, Nathan D. Pennock, Alexey V. Danilov
Summary: This study found that targeting SUMOylation can activate immune response in T cells and enhance the cytotoxic function of CD8 T cells, providing potential for immune therapy targeting SUMOylation in lymphoid malignancies.
MOLECULAR CANCER THERAPEUTICS
(2023)
Article
Oncology
Domenico Maisano, Enrico Iaccino, Alessandro D'Ambrosio, Federico Chiurazzi, Vincenzo Dattilo, Mariangela Scalise, Massimo Gentile, Eleonora Vecchio, Nancy Nistico, Annamaria Aloisio, Erika De Sensi, Giuseppe Fiume, Ileana Quinto, Selena Mimmi
Summary: The study highlights the crucial role of IgBCR in tumorigenesis of CLL B cells and proposes a phage display screening method for identifying small peptide molecules mimicking tumor IgBCR antigens. It reveals the coexistence of multiple CLL clones and suggests a potential role of CD5 receptor in autoimmunity and cell survival.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Miguel Quijada-Alamo, Claudia Perez-Carretero, Maria Hernandez-Sanchez, Ana-Eugenia Rodriguez-Vicente, Ana-Belen Herrero, Jesus-Maria Hernandez-Sanchez, Marta Martin-Izquierdo, Sandra Santos-Minguez, Monica Del Rey, Teresa Gonzalez, Araceli Rubio-Martinez, Alfonso Garcia de Coca, Julio Davila-Valls, Jose-Angel Hernandez-Rivas, Helen Parker, Jonathan C. Strefford, Rocio Benito, Jose-Luis Ordonez, Jesus-Maria Hernandez-Rivas
Summary: Our study found that concurrent biallelic ATM and TP53 loss is mutually exclusive in CLL, while monoallelic del(11q) and TP53 alterations significantly co-occur in a subset of patients with poor prognosis. CRISPR/Cas9-edited CLL cell lines revealed that combined del(11q) and TP53 mutations provide clonal advantage, whereas CLL cells with biallelic ATM and TP53 loss fail to compete in xenotransplants. Furthermore, CLL cell lines with del(11q) and TP53 mutations show partial responses to B cell receptor signaling inhibitors, indicating potential benefit from ATR inhibition.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Janek S. Walker, Zachary A. Hing, Bonnie Harrington, Jordan Baumhardt, Hatice Gulcin Ozer, Amy Lehman, Brian Giacopelli, Larry Beaver, Katie Williams, Jordan N. Skinner, Casey B. Cempre, Qingxiang Sun, Sharon Shacham, Benjamin R. Stromberg, Matthew K. Summers, Lynne Abruzzo, Laura Rassenti, Thomas J. Kipps, Sameer Parikh, Neil E. Kay, Kerry A. Rogers, Jennifer A. Woyach, Vincenzo Coppola, Yuh Min Chook, Christopher Oakes, John C. Byrd, Rosa Lapalombella
Summary: Mutations in XPO1 at E571 are associated with high-risk genetic and epigenetic features as well as accelerated progression in CLL. Overexpression of wt or mutant XPO1 in B cells can impact the development of CLL-like disease in aged mice. Concurrent expression of XPO1 with E571K or E571G mutations and TCL1 accelerates leukemogenesis.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Francesca Romana Mauro, Francesca Paoloni, Stefano Molica, Gianluigi Reda, Livio Trentin, Paolo Sportoletti, Monia Marchetti, Daniela Pietrasanta, Roberto Marasca, Gianluca Gaidano, Marta Coscia, Caterina Stelitano, Donato Mannina, Nicola Di Renzo, Fiorella Ilariucci, Anna Marina Liberati, Lorella Orsucci, Francesca Re, Monica Tani, Gerardo Musuraca, Daniela Gottardi, Pier Luigi Zinzani, Alessandro Gozzetti, Annalia Molinari, Massimo Gentile, Annalisa Chiarenza, Luca Laurenti, Marzia Varettoni, Adalberto Ibatici, Roberta Murru, Valeria Ruocco, Ilaria Del Giudice, Maria Stefania De Propris, Irene Della Starza, Sara Raponi, Mauro Nanni, Paola Fazi, Antonino Neri, Anna Guarini, Gian Matteo Rigolin, Alfonso Piciocchi, Antonio Cuneo, Robin Foa
Summary: The efficacy, safety, and discontinuation rates of the ibrutinib and rituximab regimen were investigated in previously untreated and unfit patients with chronic lymphocytic leukemia (CLL). The combination treatment showed sustained disease control in over half of the unfit patients, but careful monitoring is required to prevent and manage adverse events.
Article
Oncology
Gian Maria Zaccaria, Simone Ferrero, Eva Hoster, Roberto Passera, Andrea Evangelista, Elisa Genuardi, Daniela Drandi, Marco Ghislieri, Daniela Barbero, Ilaria Del Giudice, Monica Tani, Riccardo Moia, Stefano Volpetti, Maria Giuseppina Cabras, Nicola Di Renzo, Francesco Merli, Daniele Vallisa, Michele Spina, Anna Pascarella, Giancarlo Latte, Caterina Patti, Alberto Fabbri, Attilio Guarini, Umberto Vitolo, Olivier Hermine, Hanneke C. Kluin-Nelemans, Sergio Cortelazzo, Martin Dreyling, Marco Ladetto
Summary: In this study, machine learning techniques were applied to analyze clinical data of patients with MCL and to build a prognostic model for evaluating survival rate. This is the first application of machine learning in a prospective clinical trial on MCL lymphoma, and the developed model is expected to play a significant role in risk stratification.
Letter
Hematology
Maria Stefania De Propris, Paolo Musiu, Stefania Intoppa, Maria Grazia Nardacci, Alessandra Pucciarini, Alessia Santi, Nadia Peragine, Martina Canichella, Maria Lucia De Luca, Gianna Maria D'Elia, Ilaria Del Giudice, Alessandro Pulsoni, Brunangelo Falini, Anna Guarini, Maurizio Martelli, Enrico Tiacci, Robin Foa
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Letter
Oncology
Nadia Peragine, Maria Stefania De Propris, Stefania Intoppa, Maria Laura Milani, Francesca Romana Mauro, Antonio Cuneo, Gian Matteo Rigolin, Ilaria Del Giudice, Robin Foa, Anna Guarini
LEUKEMIA & LYMPHOMA
(2022)
Article
Oncology
Roberta Soscia, Irene Della Starza, Lucia Anna De Novi, Caterina Ilari, Michela Ansuinelli, Marzia Cavalli, Vittorio Bellomarino, Luciana Cafforio, Mariangela Di Trani, Giovanni Cazzaniga, Grazia Fazio, Alessandra Santoro, Domenico Salemi, Orietta Spinelli, Manuela Tosi, Carolina Terragna, Valentina Robustelli, Teresa Bellissimo, Gioia Colafigli, Massimo Breccia, Sabina Chiaretti, Alice Di Rocco, Maurizio Martelli, Anna Guarini, Ilaria Del Giudice, Robin Foa
Summary: Circulating tumor DNA (ctDNA) has become the most studied molecule in blood. Analysis of plasma samples from patients with different diseases revealed variations in ctDNA release, limiting its use for minimal residual disease monitoring. However, an amplification system proved effective in increasing ctDNA amounts and can be used for diagnosis and follow-up samples.
HEMATOLOGICAL ONCOLOGY
(2023)
Letter
Oncology
Riccardo Moia, Riccardo Dondolin, Maria Stefania De Propris, Donatella Talotta, Samir Mouhssine, Francesca Perutelli, Gianluigi Reda, Veronica Mattiello, Gian Matteo Rigolin, Marina Motta, Jacopo Olivieri, Renato Fanin, Omar Perbellini, Isacco Ferrarini, Francesca Romana Mauro, Ilaria Del Giudice, Luca Laurenti, Annamaria Tomasso, Massimo Gentile, Anna Maria Frustaci, Alessandra Tedeschi, Alessandro Gozzetti, Caterina Stelitano, Carlo Visco, Carol Moreno, Francesco Forconi, Roberto Marasca, Marta Coscia, Davide Rossi, Robin Foa, Gianluca Gaidano
HEMATOLOGICAL ONCOLOGY
(2023)
Letter
Hematology
Shai Levi, Yotam Bronstein, Neta Goldschmidt, Fortunato Morabito, Tomer Ziv-Baran, Giovanni Del Poeta, Osnat Bairey, Maria Ilaria Del Principe, Riva Fineman, Francesca Romana Mauro, Odit Gutwein, Gianluigi Reda, Rosa Ruchlemer, Paolo Sportoletti, Luca Laurenti, Lev Shvidel, Marta Coscia, Tamar Tadmor, Marzia Varettoni, Ariel Aviv, Roberta Murru, Andrei Braester, Annalisa Chiarenza, Andrea Visentin, Daniela Pietrasanta, Giacomo Loseto, Antonella Zucchetto, Riccardo Bomben, Jacopo Olivieri, Antonio Neri, Davide Rossi, Gianluca Gaidano, Livio Trentin, Robin Foa, Antonio Cuneo, Chava Perry, Valter Gattei, Massimo Gentile, Yair Herishanu
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Meeting Abstract
Hematology
Giovanni Manfredi Assanto, Alice Di Rocco, Francesco Malfona, Marcello Capriata, Ilaria Del Giudice, Luigi Petrucci, Paola Girardi, Gianna Maria D'elia, Maurizio Martelli, Giuseppe Gentile, Alessandra Micozzi, Alessandro Pulsoni
Article
Oncology
Giovanni Manfredi Assanto, Alice Di Rocco, Francesco Malfona, Marcello Capriata, Ilaria Del Giudice, Luigi Petrucci, Paola Girardi, Gianna Maria D'Elia, Maurizio Martelli, Giuseppe Gentile, Alessandra Micozzi, Alessandro Pulsoni
Summary: COVID-19 in lymphoma patients has a high mortality rate, but treatment with anti-SARS-CoV-2 monoclonal antibodies can decrease mortality, reduce complications, and decrease the need for oxygen support. The use of anti-COVID antibodies in vaccinated patients may improve survival rates. Active hematological disease, exposure to bendamustine, and comorbidities are independent factors predicting death.
HEMATOLOGICAL ONCOLOGY
(2023)
Letter
Hematology
Fortunato Morabito, Giovanni Tripepi, Francesca Romana Mauro, Luca Laurenti, Gianluigi Reda, Riccardo Moia, Adalgisa Condoluci, Iolanda Vincelli, Annalisa Chiarenza, Ernesto Vigna, Enrica Antonia Martino, Antonella Bruzzese, Sabrina Mezzatesta, Roberta Laureana, Giovanna Cutrona, Francesco Di Raimondo, Gilberto Fronza, Antonella Zucchetto, Riccardo Bomben, Francesca Maria Rossi, Jacopo Olivieri, Francesco Zaja, Davide Rossi, Gianluca Gaidano, Maria Ilaria Del Principe, Fiorella Ilariucci, Giovanni Del Poeta, Manlio Ferrarini, Antonino Neri, Valter Gattei, Massimo Gentile
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Letter
Hematology
Ilaria Del Giudice, Luca Vincenzo Cappelli, Julio Delgado, Carsten Utoft Niemann, Michael Asger Andersen, Emelie Hamotal Curovic Rotbain, Kathrine Aarup, Renata Walewska, Andrea Visentin, Marina Deodato, Anna Maria Frustaci, Chiara Cavalloni, Massimo Gentile, Mohamed A. Yassin, Deepesh Lad, Lydia Scarfo, Max Flogegard, Mattias Mattsson, Sara Raponi, Caterina Ilari, Irene Della Starza, Ester M. Orlandi, Alessandra Tedeschi, Livio Trentin, Gianpietro Semenzato, Anna Guarini, Paolo Ghia, Emili Montserrat, Robin Foa
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Letter
Hematology
Francesca R. Mauro, Andrea Visentin, Diana Giannarelli, Maria C. Molinari, Giulia Proietti, Marco Petrella, Francesco Angotzi, Sara Pepe, Livio Trentin, Silvia Baroncelli, Emanuela Giombini, Silvia Meschi, Fabrizio Maggi, Daniele Focosi
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Francesca R. Mauro, Diana Giannarelli, Clementina M. Galluzzo, Andrea Visentin, Anna M. Frustaci, Paolo Sportoletti, Candida Vitale, Gianluigi Reda, Massimo Gentile, Luciano Levato, Roberta Murru, Daniele Armiento, Maria C. Molinari, Giulia Proietti, Sara Pepe, Filomena De Falco, Veronica Mattiello, Luca Barabino, Roberta Amici, Marta Coscia, Alessandra Tedeschi, Corrado Girmenia, Livio Trentin, Silvia Baroncelli
Summary: This study investigated the COVID-19 morbidity in 200 chronic lymphocytic leukemia (CLL) patients after receiving the SARS-CoV-2 vaccine. The results showed that 41% of patients contracted COVID-19, with 26% requiring hospitalization and 4% dying. Age, prior treatment, and TP53 gene mutation were significantly associated with vaccine response and susceptibility. The study highlights the importance of prevention and mitigation of COVID-19 in CLL patients.
Article
Hematology
Manuel Gotti, Roberta Sciarra, Alessandro Pulsoni, Francesco Merli, Stefano Luminari, Caterina Zerbi, Livio Trentin, Alessandro Re, Chiara Rusconi, Simonetta Viviani, Andrea Rossi, Federica Cocito, Barbara Botto, Erika Meli, Antonello Pinto, Irene Dogliotti, Guido Gini, Benedetta Puccini, Francesca Ricci, Luca Nassi, Alberto Fabbri, Anna Marina Liberati, Michele Merli, Andrea Riccardo Filippi, Maurizio Bonfichi, Valentina Zoboli, Germana Tartaglia, Giorgia Annechini, Gianna Maria D'Elia, Ilaria Del Giudice, Isabel Alvarez, Andrea Visentin, Stefano Pravato, Daniela Dalceggio, Chiara Pagani, Silvia Ferrari, Caterina Cristinelli, Tanja Lazic, Virginia Valeria Ferretti, Umberto Ricardi, Luca Arcaini
Summary: In this study, baseline characteristics of 308 consecutive NLPHL patients diagnosed in 19 Italian centers from 2000 to 2018 were retrospectively analyzed. With a median follow-up of 8.4 years for treated patients, the estimated 5-year overall survival was 97.8% and 5-year progression-free survival was 84.5%. After adjusting for various factors, patients with stage II or more showed superior progression-free survival with immunochemotherapy compared to chemotherapy alone.
Letter
Hematology
Andrea Visentin, Francesca Romana Mauro, Lydia Scarfo, Massimo Gentile, Lucia Farina, Gianluigi Reda, Isacco Ferrarini, Giulia Proietti, Enrico Derenzini, Francesca Cibien, Candida Vitale, Alessandro Sanna, Daniela Pietrasanta, Monia Marchetti, Roberta Murru, Gian Matteo Rigolin, Paolo Sportoletti, Valentina Trimarco, Chiara Adele Cavarretta, Francesco Angotzi, Alessandro Cellini, Valeria Ruocco, Ivan Zatta, Luca Laurenti, Stefano Molica, Marta Coscia, Paolo Ghia, Robin Foa, Antonio Cuneo, Livio Trentin
AMERICAN JOURNAL OF HEMATOLOGY
(2023)